Discontinued — last reported Q1 '26
U.S. Pharmaceutical — Restructuring liabilities
McKesson U.S. Pharmaceutical — Restructuring liabilities decreased by 10.0% to $9.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.7%, from $14.00M to $9.00M. Over 3 years (FY 2022 to FY 2025), U.S. Pharmaceutical — Restructuring liabilities shows relatively stable performance with a -3.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A declining balance indicates that restructuring programs are nearing completion and cash outflows are subsiding.
Detailed definition
This balance sheet item represents the remaining obligations or accruals for restructuring activities within the U.S. Ph...
Peer comparison
Standard liability reporting for companies undergoing multi-year transformation or cost-saving initiatives.
mck_segment_u_s_pharmaceutical_restructuring_liabilitiesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.00M | $16.00M | $13.00M | $11.00M | $12.00M | $11.00M | $11.00M | $15.00M | $12.00M | $16.00M | $12.00M | $18.00M | $14.00M | $14.00M | $15.00M | $10.00M | $9.00M |
| QoQ Change | — | -11.1% | -18.8% | -15.4% | +9.1% | -8.3% | +0.0% | +36.4% | -20.0% | +33.3% | -25.0% | +50.0% | -22.2% | +0.0% | +7.1% | -33.3% | -10.0% |
| YoY Change | — | — | — | — | -33.3% | -31.3% | -15.4% | +36.4% | +0.0% | +45.5% | +9.1% | +20.0% | +16.7% | -12.5% | +25.0% | -44.4% | -35.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — restructuring liabilities?
- McKesson (MCK) reported u.s. pharmaceutical — restructuring liabilities of $9.00M in Q2 2025.
- How has McKesson's u.s. pharmaceutical — restructuring liabilities changed year-over-year?
- McKesson's u.s. pharmaceutical — restructuring liabilities decreased by 35.7% year-over-year, from $14.00M to $9.00M.
- What is the long-term trend for McKesson's u.s. pharmaceutical — restructuring liabilities?
- Over 3 years (2022 to 2025), McKesson's u.s. pharmaceutical — restructuring liabilities has grown at a -3.0% compound annual growth rate (CAGR), from $58.00M to $53.00M.
- What does u.s. pharmaceutical — restructuring liabilities mean?
- The amount of money the U.S. Pharmaceutical segment still owes for past restructuring activities.